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ABSTRACT
Previous animal model experiments have shown a correlation between interferon
gamma (IFN) expression and both survival from infection with attenuated rabies
virus and reduction of neurological sequelae. Therefore, we hypothesized that
rapid production of murine IFN by the rabies virus itself would induce a more
robust antiviral response than would occur naturally in mice. To test this
hypothesis, we used reverse engineering to clone the mouse IFN gene into a
pathogenic rabies virus backbone, SPBN, to produce the recombinant rabies
virus designated SPBN. Morbidity and mortality were monitored in mice infected
intranasally with SPBN or SPBN(-) control virus to determine the degree of
attenuation caused by the expression of IFN. Incorporation of IFN into the
rabies genome highly attenuated the virus. SPBN has an LD50 more than 100
fold greater than SPBN(-). In vitro and in vivo mouse experiments show that
SPBN infection enhances the production of type I interferons. Furthermore,
knockout mice lacking the ability to signal through the type I interferon receptor
(IFNAR-/-) cannot control the SPBN infection and rapidly die. These data
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suggest that IFN production has antiviral effects in rabies, largely due to the
induction of type I interferons.

IMPORTANCE
Survival from rabies is dependent upon the early control of virus replication and
spread. Once the virus reaches the CNS this becomes highly problematic.
Studies of CNS immunity to RABV have shown that control of replication begins
at the onset of T cell entry and IFN production in the CNS prior to the
appearance of virus-neutralizing antibodies. Moreover antibody deficient mice
are able to control but not clear attenuated RABV from the CNS. We find here
that IFN triggers the early production of type I interferons with the expected
antiviral effects. We also show that engineering a lethal rabies virus to express
IFN directly to the infected tissue reduces rabies virus replication and spread
limiting its pathogenicity in normal and immunocompromised mice. Therefore,
vector delivery of IFN to the brain may have the potential to treat individuals who
would otherwise succumb to infection with rabies virus.

INTRODUCTION
Rabies virus (RABV) is the type species of the lyssavirus genus in the
rhabdoviridae family. Its small, negative-stranded RNA genome encodes only
five true genes (1, 2). Although relatively simple, this zoonotic virus has a
devastating impact worldwide. The majority of human rabies deaths occur in
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children in the developing world, and it is estimated that at least 55 000 humans
die of rabies each year in Africa and Asia alone (3).

Although RABV infection historically has been viewed as a death sentence once
the virus reaches the brain, there is a small but growing number of humans who
survived rabies even though the virus entered the brain (4, 5). Due to such
cases and to research using animal models of RABV infection (6–8), many
believe that the immune system may be capable of clearing RABV from the brain
without causing irreparable immunopathology. It is clear, however, that
therapeutic intervention will be necessary in the vast majority of cases. Some
theoretical or experimental rabies treatments involve slowing virus replication
and/or spread by: induction of hypothermia (9); the highly controversial use of
therapeutic coma (5); enhancing immune cell entry into the CNS (10);
superinfection with an attenuated RABV (11, 12); and systemic or intrathecal
administration of anti-viral drugs and interferons (IFN) (13). For decades while
many researchers have been studying the effects of type I IFN (predominantly
IFN and ) during RABV infection our work has focused primarily on the role(s)
of IFN during RABV clearance from the CNS.

IFN is a pleiotropic cytokine and is the only known form of type II interferon.
Although originally discovered by its ability to “interfere” with virus infection (14),
its immunomodulatory functions were quickly recognized, and it is now widely
accepted that IFN has many important functions in both innate and adaptive

4

immunity. Some of these include: upregulation of adhesion molecules; activation
of macrophages and NK cells; T cell activation and differentiation; upregulation of
MHC molecules; antibody isotype switching; as well as induction of reactive
oxygen species and reactive nitrogen intermediates (15). These are merely a
sample of what IFN induces as it is known to affect the expression of hundreds
of genes (16). Additionally, cross-talk between type I and type II IFN has been
shown (17), suggesting IFN can amplify its anti-viral effects via the induction of
type I IFN. Furthermore, it is known that IFN can potentiate the action of type I
IFN (18) and act synergistically with them (19). Since its discovery, researchers
and clinicians have been trying to harness IFN for its potential therapeutic
effects. It has been tested experimentally as an adjuvant in vaccines (20, 21)
and as treatment in animal models of disease such as tuberculosis (22), each
with varying degrees of success. Currently the only FDA-approved uses for IFN
in humans are treatments for chronic granulomatous disease (23) and
osteopetrosis (24), but IFN is also prescribed by veterinarians to treat canine
atopic dermatitis (25). These clinical uses of IFN highlight its pleiotropic nature
as the mechanisms of action in these diseases are through enhanced innate
immunity, activation of osteoclasts and suppression of the adaptive immune
response, respectively.

Our previous work has shown that IFN mRNA expression in the brains of mice
infected with attenuated RABV strongly correlates with blood-brain barrier (BBB)
permeability changes and clearance of RABV from the CNS (6, 26). Recent
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experiments confirm the importance of IFN during RABV clearance from the
CNS, supporting the concept that IFN is at the center of the signaling pathway
that alters tight junction protein expression and leads to increased BBB
permeability and survival from RABV infection (27). These rabies-specific data,
as well as the more commonly known roles of IFN in the innate and adaptive
arms of the immune response, suggest that therapeutically enhancing IFN
expression in the CNS during a rabies infection may prevent virus spread and aid
the clearance of RABV from CNS tissues through a number of mechanisms.
Therefore, to more precisely determine the effects of IFN expression in the CNS
on pathogenic RABV infection, we engineered a pathogenic RABV to express the
murine IFN gene. We report that RABV-expressed IFN highly attenuates a
pathogenic RABV in mice, and that this attenuation is due, at least in part, to
upregulation of type I IFN.

MATERIALS AND METHODS:
Mice. Female Swiss Webster mice were purchased from Taconic Farms
(Germantown, NY). Female C57Bl/6J mice and IFN-/- mice on a C57Bl/6
background were purchased from Jackson Laboratories (Bar Harbor, ME).
WT129 and IFNAR-/- mice were from investigator breeding colonies maintained at
Thomas Jefferson University and were originally provided by Michel Aguet (28).
All mouse experiments were approved by the Thomas Jefferson University
Institutional Animal Care and Use Committee.
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Cell lines. BSR cells (a BHK-21 clone) (29) grown in DMEM (Mediatech,
Manassas, VA) supplemented with 10% FBS (Atlanta Biologicals, Flowery
Ranch, GA) were used to grow virus stocks. Mouse neuroblastoma cells (NA)
were grown in RPMI medium 1640 (Mediatech, Manassas, VA) and used for
growth curves, virus titers and immunofluorescence. Mouse astrocytoma (AS)
cells and monocyte lineage (MC) cells were grown in DMEM supplemented with
10% FBS and were used for growth curves.

Viruses. SPBN, the prototype recombinant RABV was derived from the
SADB19 strain (30, 31). Although SPBN is often referred to as a vaccine vector,
when administered to mice intranasally (i.n.), it is highly pathogenic. The wild
type RABV strain DRV4 was isolated from a human rabies victim and propagated
in NA cells as previously described (32).

Construction of recombinant viruses. The recombinant RABVs, SPBN(-) and
SPBN, were engineered as described previously (33). For SPBN, murine IFN
DNA was PCR-amplified from mRNA extracted from RABV-infected mouse brain
tissue using the custom primers (IDT, Coralville, IA) below and DeepVent
polymerase (NEB, Ipswich, MA). The forward primer,
5’ATAGAATTCCGTACGAAGATGAACGCTACACACTGCATCTTGGCT3’,
contains a BsiWI restriction site, start codon, and the gene specific sequence.
The reverse primer,
5’ATTCTCTAGATAGCTAGCTCAGCAGCGACTCCTTTTCCGCTTCCT3’,
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contains a NheI restriction site, stop codon, and the gene specific sequence.
The resultant IFN DNA was cloned into the pSPBN plasmid, creating the
pSPBN plasmid. Standard transformation and transfection methods were used
to complete the virus rescue of SPBN as outlined above.

Growth Curves. NA, AS or MC cells were infected at a multiplicity of infection
(MOI) of 0.01 for multi-step and 1 for single-step growth curves. 100 ul
supernatant aliquots were taken at 0, 24, 48 and 72 hours post-infection. Virus
titers from the supernatants were calculated as described below.

Virus Titers. To determine virus titers, NA cells were seeded into 96 well plates,
grown for two days and then infected with virus in serial ten-fold dilutions. Two
days post-infection (d.p.i.), the cells were fixed with 80% acetone and stained
with FITC-conjugated anti-RABV RNP antibody (Fujirebio Diagnostics, Malvern,
PA). Virus titers of triplicate samples were determined using a fluorescence
microscope.

Immunofluorescent staining. NA cells were grown in culture well slides for 24
hours and then infected with RABV at an MOI=0.1. 24 hours later, cells were
stained for the presence of RABV and mouse IFN using FITC-conjugated antiRABV RNP antibody and PE-conjugated anti-mouse IFN antibody (Sigma, St.
Louis, MO), respectively. Slides were mounted using ProLong Gold with DAPI
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(Life Technologies, Eugene, OR). Photos were taken using a DM6000B
fluorescent microscope (Leica, Buffalo Grove, IL).

Infection of mice. Groups of mice were infected under isoflurane (Vedco, St.
Joseph, MO) anesthesia: intracranially (i.c.) with 103 focus-forming units (ffu) in
10 ul PBS or intranasally (i.n.) with 10 3-106 ffu in 20 ul PBS. Mice were observed
for at least 30 days for appearance of clinical signs of rabies such as limb
paralysis, tremors and weight loss. Mice were humanely euthanized when
moribund or after losing greater than 30% of starting body weight.

IFNTreatment. Cells were treated with 10, 100 or 1000U of recombinant mouse
IFN (BD Biosciences, San Jose, California) at 24 and 48 hours post-infection by
addition to the culture medium.

Enzyme-Linked Immunosorbent Assay (ELISA). 50 ul aliquots of virusinfected supernatants were assayed for IFN using an OptEIA Mouse IFN Kit II
(BD Biosciences, San Jose, CA) or for IFN using a Mouse IFN-alpha Platinum
ELISA kit (eBioscience, Vienna, Austria) per manufacturers’ instructions. The
plates were then scanned in a Synergy H1 plate reader (BioTek, Winooski, VT)
and absorbance at 450 nm was recorded.

Quantitative PCR. RNAtot was extracted from brain samples using a Qiagen
RNeasy kit (Qiagen, Valencia, CA) and modified Qiagen protocol previously
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described (6). Briefly, tissues were homogenized by aspirating through a sterile,
20 gauge needle approximately 15 times in TriReagent (MRC, Cincinnati, OH).
Homogenized samples were spun in a Heraeus Biofuge pico benchtop centrifuge
(Thermo Scientific, Langenselbold, Germany) at 12 000 rpm for 15 min at RT.
The aqueous layer was removed and mixed with an equal portion of 70% ethanol
and then added to the Qiagen spin column. All subsequent steps are outlined in
the Qiagen manual, including the optional on-column DNAse I digestion which
was used. After RNAtot extraction, cDNA was prepared using oligo dT 15 primers,
dNTP and Moloney Murine Leukemia Virus Reverse Transcriptase (Promega,
Madison, WI) as described previously (6). Finally, each sample was analyzed for
the presence of specific mRNAs by qPCR using a Biorad iCycler, iQ Supermix or
iQ Sybr (BioRad, Hercules, CA), and primer/probe sets (IDT, Coralville, IA)
designed as follows: CD4 F AGGTCTCGCTTCAGTTTGCT, R
AGCCACTTTCATCACCACCA, Pr TGGCAACCTGACTCTGACTCTGGACA;
CD8 F CATCCTGCTTCTGCTGGCATT, R TGGGCGCTGATCATTTGTGAAA, Pr
TGTGTGCGGAGGAGAGCCCGAATTCA; CD19 F
GAGCTCAGAGCCATGAAACA, R CAAGGTTGGAGTCGTTCTCA, Pr
CCAGACAGCGAGGAGGGCTCTGAAT; IFN F
AGCAACAACATAAGCGTCATT, R CCTCAAAACTTGGCAATACTCA, Pr
ACCTTCTTCAGCAACAGCAAGGGC; SPBN-N F
AGAAGGGAATTGGGCTCTG, R TGTTTTGCCCGGATATTTTG, Pr
CGTCCTTAGTCGGTCTTCTCT; L13 F CTACAGTGAGATACCACACCAAG, R
TGGACTTGTTTCGCCTCCTG, Pr ATCCACAAGAAAGTGGCTCGCACCAT;
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IFN F ATTTTGGATTCCCCTTGGAG, R TGATGGAGGTCATTGCAGAA; IFN
F CACAGCCCTCTCCATCAACT, R GCAACCACCACTCATTCTGA.

Statistical Analysis. All calculations were performed using GraphPad Prism
5.01 (GraphPad Software, San Diego, CA) with the exception of the Habel Test
for Potency (34).

RESULTS
Recombinant rabies virus expresses murine IFN. Recombinant RABVs were
constructed using the pathogenic SPBN backbone vector. Fig. 1A shows a wildtype RABV genome while 1C depicts the IFN-expressing SPBN, termed SPBN.
To control for any changes in replication efficiency that might occur due to
increased size of the RABV genome, we used the previously constructed SPBN() (Fig. 1B). SPBN(-) has an inactivated tumor necrosis factor  (TNF) gene in
lieu of murine IFN.

To ensure that SPBN can produce murine IFN, we infected NA cells grown on
culture well slides with SPBN or SPBN(-) at an MOI =0.1. 24 hours p.i. the cells
were fixed, permeabilized and stained for evidence of RABV infection and murine
IFN production. Fig. 2 shows the results of immunostaining for RABV and IFN
of uninfected (A), SPBN(-) (B) and SPBN (C) infected NA cells. While cells
infected with SPBN(-) are positive only for RABV, the SPBN-infected cells
stained positive for both RABV and IFN, demonstrating that our recombinant
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SPBN produces IFN. We next used ELISA to analyze the supernatants of NA,
AS and MC cell lines infected with SPBN or SPBN(-) for the presence of IFN.
Fig. 2D shows that by 12 hours p.i. significant amounts of IFN are produced and
secreted into the supernatants of all cell types infected with SPBN but not
SPBN(-).

Virus-encoded IFN has differential effects on RABV replication in vitro. To
determine the effects of IFN expression on RABV replication in relevant cell
types, we infected NA, AS and MC cell lines with SPBN or SPBN(-) (Fig. 3) As
shown in Fig. 3A and 3D, there is less than one log10 difference in virus
replication and spread between SPBN and SPBN(-) in NA cells by 48 hours p.i.
Both viruses grow to relatively high titers (>107 ffu/ml). In AS cells there is a
similar result with less than one log10 difference in growth by 48 hours p.i. in the
single-step growth curve (Fig. 3B). IFN production may slow the spread of
SPBN in AS cells, however, as there is greater than one log10 difference
between the virus titers at 72 hours p.i. (Fig. 3E). In contrast to the minor
differences seen in NA and AS cell lines, the replication rate and spread of
SPBN in MC cells is several logs10 lower as compared to SPBN(-) (Fig. 3C, 3F).
The antiviral mechanisms in the MC cells appear to be very rapidly activated, as
this multi-log difference in replication is evident as early as 24 hours p.i. This
significant decrease in SPBN replication as compared to SPBN(-) indicates that
the IFN produced by SPBN and measured by ELISA (Fig. 2D) is indeed
functional. Although SPBN replication is hampered in MC cells, substantial
12

numbers of progeny virions (~103 ffu/ml) were still produced, indicating that even
in an immune cell line highly responsive to IFN, SPBN is able replicate and
spread.

IFN attenuates pathogenic RABV. After demonstrating the ability of SPBN to
replicate well in permissive cells and produce IFN in vitro, we examined the
pathogenicity of SPBN(-) and SPBN in vivo. Groups of ten Swiss-Webster mice
were infected i.n. with 103 – 106 ffu of SPBN or SPBN(-). Mice were monitored
for mortality and morbidity for 30 days. The resultant survivorships (Fig. 4A and
4C) clearly demonstrate the attenuation of the pathogenic SPBN vector by the
addition of IFN to its genome. The most striking difference in pathogenicity
occurs at 105 ffu where 90% of SPBN mice survive infection while 100% of mice
infected with SPBN(-) succumb within 15 days, but SPBN is significantly
attenuated at all doses compared to SPBN(-). To quantify the attenuation of
pathogenicity due to IFN, we calculated the LD50 of SPBN and SPBN(-) and
found greater than a two log10 difference between the viruses (Fig. 4B). It should
be noted that the exact difference could not be calculated because infection with
all doses of SPBN(-) killed more than 50% of the mice. Thus, the expression of
IFN from the RABV genome decreased the pathogenicity of SPBN by more than
100 fold when administered i.n.

SPBN replication is diminished while IFN expression is elevated in the
CNS of infected mice. Having demonstrated that IFN expression by RABV has
13

differential effects on virus replication in various cell types in vitro, we next
infected groups of C57BL/6 mice with SPBN or control SPBN(-) to quantify virus
replication and IFN gene expression in the CNS. At 10 d.p.i. viral nucleoprotein
(N) RNA expression in both the cerebellum and cortex is approximately ten fold
lower in mice infected with SPBN than SPBN(-) (Fig. 5A). Despite the reduced
replication, the cerebellum and cortex of the SPBN-infected mice showed
approximately ten fold greater IFN mRNA levels than in SPBN(-)-infected mice
(Fig. 5B). Taken together, these data show that at 10 d.p.i. SPBN induces
greater than 100 fold more IFN expression per viral N message in the CNS of
mice than SPBN(-) (Fig. 5C).

SPBN infection does not increase immune cell infiltration into the CNS. In
other animal models, immune cell infiltration into the CNS has been shown to be
essential for RABV clearance (eg. 8, 35). To determine whether enhanced
immune cell infiltration could play a role in the attenuation of SPBN, we
measured the expression of mRNA specific for CD4+, CD8+ and CD19+ cells as
an estimation of T and B cell influx into the CNS of mice infected with SPBN or
SPBN(-) (Fig.6). At 10 d.p.i. we found no significant increase in immune cell
markers in the brains of SPBN-infected as compared to SPBN(-)-infected mice.
In fact, the SPBN(-)-infected mice showed increased expression of T cell marker
CD8 in both the cerebellum (CB) and cortex (CX).
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SPBN attenuation occurs in the absence of endogenous IFN or
antibodies. Previously it has been suggested that IFN-producing T cells as well
as virus-neutralizing antibodies (VNA) are important for the clearance of RABV
from the brain (36, 37). To determine if endogenously produced IFN or VNA are
essential for SPBN attenuation, we infected groups of IFN-/- mice, having no
endogenous IFN, and groups of JHD-/- mice, lacking functional B cells and
antibodies, with SPBN or SPBN(-). At 16 d.p.i. 100% of SPBN-infected IFN-/mice were alive compared to only 11% of those infected with SPBN(-) (Fig. 7A).
We continued to monitor the mice until 35 d.p.i., at which time 75% of IFN-/- mice
infected with SPBN remained alive while only 11% of SPBN(-)-infected mice
survived. As seen in Fig. 7B, SPBN(-)-infected IFN-/- mice also begin to lose
weight earlier than their SPBN-infected counterparts.

The importance of antibody to RABV clearance from the brain is well established.
Therefore, we infected JHD-/- mice to determine if IFN overexpression could
prevent or delay death in the absence of antibody. Infection of J HD-/- mice yields
a similar outcome to that seen with IFN-/- mice. By 17 d.p.i. all SPBN(-)-infected
JHD-/- mice succumbed to rabies infection while 100% of those infected with
SPBN remained alive (Fig. 7C). By the end of the experiment, at 32 d.p.i., 92%
of JHD-/- mice infected with SPBN survived, despite having no functional,
circulating antibodies. As can be expected, the mice infected with SPBN(-) lost
weight faster than those infected with SPBN (Fig. 7D). Although most of the
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mice were sacrificed at day 32, we continued to monitor five SPBN-infected
JHD-/- mice. Surprisingly, 5 of 5 of these mice survived for 75 days, 4 of 5
survived 87 days, and 3 of 5 remained alive for 88 days, at which time this
experiment was concluded (data not shown). Thus even this severe immune
deficit does not prevent long-term control of SPBN infection by the host.

IFNAR-/- mice do not survive SPBN infection. IFNAR-/- mice are
unresponsive to type I IFN because the IFNAR1 chain of the heterodimeric
receptor is knocked out (28). Based on knowledge that IFN can potentiate type
I IFN effects as well as act synergistically with type I IFN, we infected groups of
IFNAR-/- mice, as well as their background control WT129 mice, with SPBN or
SPBN(-) to determine the role of type I IFN in attenuation of SPBN. 100% of
IFNAR-/- die from infection with SPBN by 14 d.p.i., and this is not significantly
different from the control SPBN(-)-infected IFNAR-/- mice which all die by 13
d.p.i.. The WT129 background does not significantly alter the strong attenuation
of SPBN seen in Swiss-Webster mice as 86% of SPBN-infected WT129 mice
survive for 31 days while 100% of these animals infected with SPBN(-) die.

SPBN induces early Type I IFN expression in vitro and in vivo. There is
substantial overlap in the regulation of type I and type II IFN (38). The early or
increased expression of IFN by SPBN may increase the expression of type I
IFN, thereby enhancing the innate immune response to RABV and protecting
mice from death during SPBN infection. To test this theory, we infected flasks of
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MC cells with SPBN or SPBN(-) and measured virus- and IFN-specific mRNA
levels in these cells at various timepoints post-infection. Infection of MC cells
with SPBN leads to an early and sustained overexpression of IFN (Fig. 9A) and
induces a significant increase in IFN expression as compared to SPBN(-)
infection from 6 to 48 hours p.i. (Fig. 9B). This effect is also seen when
measuring IFN induction (Fig. 9C), however, IFN expression continues to rise
in the SPBN(-)-infected MC cells, becoming significantly higher in these cultures
by 24 hours p.i. The increase in type I IFN expression in SPBN(-)-infected MC
cells during the later timepoints is most likely the result of more rapid virus
replication, as evidenced by the viral N message levels (Fig. 9A-C). SPBN
replication remains very low throughout the experiment but induces relatively
high type I and type II IFN expression. The addition of IFN to cultures of
SPBN(-)-infected MC cells reduces viral replication (Fig. 9D) in concert with
increasing IFN levels (Fig. 9E) at early timepoints. Elevated IFN levels, which
are only seen in the presence of both IFN and virus infection, are particularly
evident at 24 hrs of culture (Fig. 9F).

To determine if SPBN also induces higher levels of type I IFN in the brain than
SPBN(-), we infected groups of C57BL/6 mice with either virus. We sacrificed
the mice at early timepoints during infection and analyzed the samples by qPCR
for the presence of viral RNA as well as type I and type II IFN mRNA. It is widely
held that IFN expression levels increase as virus replication increases (39). In
fact, mice dying from RABV and other related viruses, often have highest levels
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of circulating IFN just before death (40). Therefore, we compared IFN
expression levels to the amount of virus replication in the olfactory bulb (OB)
(Fig. 10A,D,G), cerebellum (CB) (Fig. 10B,E,H) and cerebral cortex (CX) (Fig.
10C,F,I) of infected mice. After normalizing the IFN message levels to RABV N
mRNA, it is clear that SPBN induces significantly higher levels of IFN (Fig. 10AC) and type I IFN (Fig. 10D-I) per viral message than does SPBN(-). Relative
levels of IFN, IFN and IFN expression were significantly increased in SPBNinfected OB at 4, 6 and 8 d.p.i. as compared to SPBN(-)-infected OB (Fig.
10A,D,G). In the CB and CX, expression of type I IFN was significantly
increased at 6 and 8 d.p.i. (Fig. 10E,F,H,I). No SPBN virus was detected in
these samples at day 4 p.i. likely due to the time required for the spread of
SPBN to those brain regions from the OB. The relative level of IFN was
significantly increased in SPBN-infected CB at 8 d.p.i. (Fig. 10B) and both 6 and
8 d.p.i. in the CX (Fig. 10C), as compared to SPBN(-)-infected tissues.

DISCUSSION.
IFN is a pleiotropic cytokine capable of modulating both the innate and adaptive
immune responses and, as hypothesized, the addition of murine IFN to the
genome of SPBN highly attenuated the pathogenicity of this virus in mice. To
determine which IFN-inducible antiviral mechanism(s) led to the strong
attenuation of the RABV, we infected cell lines relevant to RABV infection as well
as wild-type mice and knock-out mice with specific immune deficits. Together
the data support the concept that IFN production by SPBN attenuates the virus
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by enhancing the production of type I IFNs early in the infection. Thus IFN, an
important product of adaptive immunity, inhibits RABV replication by activating
well-established innate antiviral mechanisms.

We previously showed a significant correlation exists among IFN expression,
BBB permeability and RABV clearance from the CNS (6, 26). The changes in
BBB permeability are necessary to allow immune effectors to enter the CNS and
eliminate the RABV infection. Various studies suggest that the mechanism
involves IFN-mediated induction of radicals (26, 41), which culminates in the
alteration of tight-junction proteins (27). In the present study, however, we did
not observe an increase in BBB permeability due to IFN overexpression. While
pathogenic when administered intranasally, the control SPBN(-) virus, unlike
wild-type RABV (42), induces BBB permeability and allows immune cells to
infiltrate the brain. In fact, we showed that SPBN(-) infection resulted in a
significant increase in immune cell markers in some brain regions as compared
to SPBN infection, despite having much lower levels of IFN expression. This
seemingly paradoxical result is most likely the result of decreased SPBN
replication necessitating the influx of fewer immune cells to clear the infection, as
compared to the SPBN(-) infection. Since SPBN(-) is pathogenic, despite
triggering functional changes in the BBB and immune cell invasion into the
infected CNS, we can conclude that viral IFN expression has additional
therapeutic effects on RABV infection.
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Since it is known that production of VNA is important for protection against RABV
infection, and IFN is capable of affecting the humoral adaptive response against
viruses, we studied SPBN infection in JHD-/- mice which have no functional B
cells and produce no antibodies. Interestingly, the substantial attenuation of
SPBN is not the result of earlier or greater production of antibodies, as
evidenced by the survival of 92% of SPBN-infected B cell deficient mice 32 d.p.i.
In actuality, addition of IFN to a vaccine RABV strain could even suppress VNA
induction due to lower viral replication. Our data support the concept that
circulating antibody may not be the best indicator of vaccine efficacy as IFN
could be affecting T cell memory or memory in other cell types that are not
evident when judging vaccine efficacy only by the induction of serum VNA (43).
It should be noted that antibody is not required for long-term survival from RABV
in the context of IFN overexpression in our experiments. Nevertheless, these
data do not refute the numerous reports that VNA are essential for the clearance
of RABV in the absence of such therapeutic intervention.

Previous findings suggest that IFN-producing T cells play an important role in
the clearance of RABV (6, 26, 36, 44), as well as other neurotropic viruses (45,
46), from the CNS of mice. Additionally, little is known about the role of NKderived IFN during RABV infection. To determine if the cellular source of IFN is
essential for a therapeutic effect, we infected IFN-/- mice with SPBN(-) or
SPBN. We found that the majority of SPBN-infected mice survived while
SPBN(-)-infected IFN-/- mice did not. Since we used i.n. infection, and RABVs
20

primarily infect neurons, it is not likely that infected T or NK cells were a major
source of RABV-encoded IFN in the CNS. Therefore, during SPBN infection of
mice, the production of IFN by classical immune cells does not appear to be
essential for survival. Furthermore, the survival of SPBN-infected IFN-/- mice
demonstrates that only virus-encoded IFN is necessary for protection and
endogenous IFN production by NK or T cells is not required. Together, these
IFN-/- and JHD-/- data show that attenuation of RABV by IFN is profound in adult
mice and it is not dependent upon the early production of VNA or an immune
source of IFN.

Analysis of our in vitro monocyte infection experiments leads us to consider that
the stimulation of type I IFN expression by IFN contributes to survival from
SPBN infection. Experiments performed over the last several decades have
questioned the importance of type I IFN during RABV infection. Although some
early experiments found type I IFN expression to be inconsequential to the fate of
the RABV-infected animal (39) or equivocal (47), other reports suggest an
important role for type I IFN (7, 48). Measuring IFN levels late in the course of
infection as well as focusing on survival as an estimation of IFN efficacy may
have contributed to the confusion as to the importance of type I IFN. One of the
early experiments showed that there are two waves of type I IFN expression
during wild-type RABV infection (40). Very early expression of type I IFN is
important for survival, while the second wave of expression is not therapeutic and
is likely the result of uncontrolled RABV replication (40). More recent work has
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demonstrated that type I IFN can impede replication and spread of a highly
neuroinvasive RABV both in vitro and in vivo and can delay/reduce mortality but
cannot prevent death altogether (48). Furthermore, an engineered RABV-based
HIV vaccine vector expressing IFN is attenuated by its IFN production (49).
Still other experiments have shown that attenuated RABV induce high levels of
type I IFN while wild-type RABV do not (7). Since type I IFN signaling is
important for protection against infection, it is not surprising that the RABV virus
itself dedicates substantial resources to blocking type I IFN signaling. Both the N
and P genes of RABV express products that interfere with type I IFN signaling
(50, 51) and mutating P can attenuate the virus (52). The blockade of type I IFN
by RABV is a “leaky” process, however, and the host response is able to impede
replication and spread to some degree despite this immunoevasion strategy (48).

The attenuation of SPBN is profound in a number of wild-type mouse strains as
well as those with severe immune deficits. When we infected IFNAR -/- mice with
SPBN, however, the overexpression of IFN could not compensate for this
immune deficiency, and the mice quickly died. This result again underscores the
importance of type I IFN and suggests the mechanism by which SPBN is
attenuated. Together, our in vitro and in vivo data showing highly increased type
I IFN expression from cell lines and brain tissue infected with SPBN over
SPBN(-) as well as the lack of attenuation of SPBN in IFNAR-/- mice, suggest
that expression of IFN induces the expression of type I IFN, and that enhancing
type I IFN signaling plays a vital role in the attenuation of SPBN.
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Although IFN induces hundreds of genes involved in other antiviral mechanisms,
we have shown that a major mechanism of SPBN attenuation is through the
induction of type I IFN. This rapid type I IFN expression only occurs when an
IFN-responsive cell is exposed to the virus. This mechanism may circumvent
the IFN evasion tactics of the RABV, leading to control of virus replication and
spread and, ultimately, virus clearance.

Altogether, our results indicate that the expression of IFN by RABV renders it
attenuated even in mice with severe immune deficits. The fact that the
replication and spread of RABV in the CNS is controlled by immune mechanisms
long before neutralizing antibody is produced has long been enigmatic in rabies
and understanding the process may hold the key to therapy. Our work shows
that IFN produced early in the immune response to RABV likely uses innate
mechanisms to control the infection such that the later appearance of antibody
can clear the infection.
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FIGURE LEGENDS

Figure 1. RABV constructs. A, The negative-stranded RNA genome of the
wild-type (WT) parental vector, SAD B19, which was used as the backbone to
construct two RABV viruses used for all subsequent experiments. The control
virus, SPBN(-), which contains a cytokine gene (red crosshatch), inactivated by
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the substitution of STOP codons for the initial seven START codons, is shown in
B. C represents the interferon gamma-expressing RABV, SPBN. N,
nucleoprotein; P, phosophoprotein; M, matrix protein; G, glycoprotein; L, large
catalytic subunit of the viral polymerase; TGA, STOP codon; , murine IFN
gene.

Figure 2. IFN Production. NA cells were infected at an MOI=0.1 and stained 24
hours later for the presence of RABV and IFN (A-C). NA, AS and MC cells were
infected at an MOI=1 and the supernatants were analyzed by IFN-specific
ELISA 12 hours p.i. A, uninfected control NA cells; B, SPBN(-)-infected cells; C,
SPBN-infected cells. D, IFN concentration in supernatants. All photos are
280x magnification. Significance determined by student’s t test. **, p0.01; ***,
p0.001.

Figure 3. Virus Growth Curves. NA, AS and MC cell lines were infected with
SPBN(-) or SPBN RABV at an MOI=1 for single step growth curves (A-C) and
MOI=0.01 for multi-step growth curves (D-F). Supernatant virus titers were
measured at the indicated times post-infection.

Figure 4. In vivo mouse infection. Groups of ten Swiss-Webster mice were
infected i.n. with SPBN or SPBN(-) RABV and monitored for mortality. 4A
shows absolute survival proportions for each dose of virus used to calculate the
LD50 in 4B. 4C is the Kaplan Meier plot indicating both death and time to death.
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LD50 was calculated by the Habel Test for Potency. Significant difference
between survival curves was determined by the Mantel-Cox test. ***, p0.001.
#, LD50 for SPBN(-) could not be accurately calculated because all SPBN(-)
doses killed more than 50% of mice.

Figure 5. IFN expression and RABV replication in the brain. Groups of five
C57BL/6 mice were infected i.n. with SPBN or SPBN(-) RABV. Ten d.p.i. brains
were analyzed for the presence of specific mRNA. A shows copies of viral
nucleoprotein mRNA, while B shows copies of IFN mRNA. C shows IFN/N
expression illustrated as fold change in the brains of SPBN-infected as
compared to control SPBN(-)-infected mice. All copy numbers have been
normalized to the L13 housekeeping gene. Significance determined by the
Mann-Whitney test. **, p0.01.

Figure 6. Adaptive immune cell markers in the brain. Groups of five
C57BL/6 mice were infected i.n. with SPBN or SPBN(-) RABV. Ten dpi brains
were analyzed for the presence of specific mRNA. Normalized mRNA copy
numbers of CD4, CD8 and CD19 in the brains of RABV-infected mice are
depicted in A, B and C, respectively. All copy numbers are normalized to the L13
housekeeping gene. Significance determined by the Mann-Whitney test. *,
p0.05.
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Figure 7. Infection of IFN-/- and JHD-/- mice. Groups of 8-9 IFN-/- mice (A
and B) and groups of 13-14 JHD-/- mice (C and D) were infected i.n. with 105 ffu
of SPBN(-) or SPBN and monitored for mortality and morbidity for 35 and 32
days, respectively. The survival curves are shown in A and C. Weight loss as an
indicator of infection is shown in B and D. Significant difference between survival
curves determined by the Mantel-Cox test. Significant differences in weight loss
determined by the student’s t test. **, p0.01; ***, p0.001.

Figure 8. Infection of IFNAR-/- mice. Groups of 6-7 WT129 (A) or IFNAR-/- (B)
mice were infected i.n. with 105 ffu of SPBN or SPBN(-) and monitored for
mortality and morbidity. Significance was determined by the Mantel-Cox test.
***, p0.001.

Figure 9. In vitro induction of type I interferon. MC cells were infected with
SPBN or SPBN(-) at an MOI=10. In A, B, C cultures were analyzed at the
indicated timepoints for levels of mRNA specific for RABV N versus IFN, IFN
and IFN. Bars represent normalized IFN mRNA levels plotted on the left Y axis
and lines are normalized viral N mRNA expression plotted on the right Y axis.
IFN was added to the cell cultures in D, E, F and virus titers (D) as well as IFN
levels (E, F) assessed. F shows IFN levels in the cultures at 24 hrs p.i.
Significant differences in cytokine levels between SPBN(-) and SPBN infected
cultures (A-C) and control versus treated cultures (F) were determined by
student’s t test.
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Figure 10. In vivo induction of type I interferon. Groups of C57BL/6 mice
were infected i.n. with 105 ffu of SPBN or SPBN(-)and their brain sections were
analyzed for the gene products denoted above. Expression levels are
normalized to the L13 housekeeping gene. Significant differences were
determined by the Mann-Whitney test. *, p0.05; **, p0.01; ***, p0.001.
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